Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536743 | 1.00 | MEN1 (0.56) | MEN1KMT2AKDRCSF1RKIT | |
| SCHEMBL23500689 | 0.87 | GAA (0.54) | MEN1KMT2AKDRKITFLT3 | |
| SCHEMBL19263436 | 0.85 | KMT2A (0.56) | MEN1KMT2ACSF1RFLT3SMN1; SMN2 | |
| SCHEMBL3188022 | 0.80 | MEN1 (0.50) | MEN1KMT2AKDRCSF1RKIT | |
| SCHEMBL27983617 | 0.80 | KMT2A (0.56) | MEN1KMT2AKDRCSF1RKIT | |
| SCHEMBL29536398 | 0.79 | AKT1 (0.44) | KDRFLT1FLT4FLT3RAB9A | |
| Hydrochloric Acid SCHEMBL29536731 | 0.78 | KMT2A (0.57) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL29536538 | 0.78 | POLB (0.47) | KMT2AKDRKITFLT3SMN1; SMN2 | |
| SCHEMBL23501077 | 0.78 | POLB (0.47) | KMT2AKDRKITFLT3SMN1; SMN2 | |
| SCHEMBL4291228 | 0.77 | NPC1 (0.56) | MEN1KMT2AKDRCSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939948-B | Novel quinazoline-containing compound, intermediate and application thereof | 苏州美诺医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2021115432-A1 | NOVEL QUINAZOLINE-CONTAINING COMPOUND, AND INTERMEDIATE THEREOF AND USE THEREOF | 苏州长禾药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115432-A1 | NOVEL QUINAZOLINE-CONTAINING COMPOUND, AND INTERMEDIATE THEREOF AND USE THEREOF | 苏州长禾药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| CN-112939948-A | Novel quinazoline-containing compound, intermediate and application thereof | 苏州长禾药业股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-29 | — | — | US | disclosed |
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | disclosed |
| WO-2013143466-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVE AS AURORA KINASE INHIBITOR | 广东东阳光药业有限公司 (CN) | 2013-10-03 | — | — | WO | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| CN-100349906-C | Phosphonoxyquinazoline derivatives and pharmaceutical use thereof | ASTRAZENECA AB (SE) | 2007-11-21 | — | — | CN | disclosed |
| CN-101074227-A | Phosphine acyloxy quinazoline derivatives and their medicine using | ASTRAZENECA AB (SE) | 2007-11-21 | — | — | CN | disclosed |
| EP-1847539-A1 | Quinazoline derivatives | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | disclosed |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| CN-1764668-A | Phosphonoxyquinazoline derivatives and pharmaceutical use thereof | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | CN | disclosed |
| EP-1578755-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| US-6916820-B1 | Neurotrophic substituted pyrimidines | KRENITSKY PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| US-6583148-B1 | Neurodegenerative or other neurological disorders; enhancing the effect of nerve growth factor; 2-Amino-5-(4-chlorophenoxy)-4-trans-4-hydroxycyclohexylamino) pyrimidine | KRENITSKY PHARMACEUTICALS, INC. | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | MEN1 1577/4885KMT2A 3116/4885KDR 2145/4885 |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ABL1, NQO1, NQO2 | MEN1 748/4885KMT2A 1309/4885KDR 1513/4885 |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | AURKA, AURKC, AURKB | MEN1 1530/4885KMT2A 370/4885KDR 642/4885 |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | SLC10A1, GLS, SLC10A2 | MEN1 3798/4885KMT2A 2859/4885KDR 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.